Nevirapine
- Generic Name
- Nevirapine
- Brand Names
- Viramune
- Drug Type
- Small Molecule
- Chemical Formula
- C15H14N4O
- CAS Number
- 129618-40-2
- Unique Ingredient Identifier
- 99DK7FVK1H
- Background
A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
- Indication
For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naรฏve HIV-1 Positive Subjects
- First Posted Date
- 2007-10-05
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 21
- Registration Number
- NCT00540137
- Locations
- ๐ฌ๐ง
Heart of England NHS Foundation Trust, Birmingham, United Kingdom
๐ฌ๐งSt. Mary's Hospital, London, United Kingdom
Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving Rifampin
- First Posted Date
- 2007-06-06
- Last Posted Date
- 2011-11-22
- Lead Sponsor
- Bamrasnaradura Infectious Diseases Institute
- Target Recruit Count
- 142
- Registration Number
- NCT00483054
- Locations
- ๐น๐ญ
Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand
Study to Evaluate the Replacement of Reverse Transcriptase Nucleoside/Nucleotide Inhibitors by Nevirapine in Patients on Triple Treatment With Analogues Only
- First Posted Date
- 2006-12-22
- Last Posted Date
- 2008-10-31
- Lead Sponsor
- Hospital de Calella
- Target Recruit Count
- 28
- Registration Number
- NCT00415090
- Locations
- ๐ช๐ธ
Hospital La Candelaria, Tenerife, Canarias, Spain
๐ช๐ธHospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
๐ช๐ธHospital.Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
Efavirenz to Nevirapine Switch and Low-Density Lipoprotein (LDL)-Dyslipidemia
- Conditions
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2010-10-28
- Lead Sponsor
- University Hospital, Caen
- Target Recruit Count
- 40
- Registration Number
- NCT00405171
- Locations
- ๐ซ๐ท
Cรดte de Nacre University hospital, Caen, France
Drug Levels of Tablet and Liquid Forms of Lamivudine, Nevirapine, and Stavudine in HIV Infected Thai Children
- Conditions
- Interventions
- First Posted Date
- 2006-04-07
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 44
- Registration Number
- NCT00312091
- Locations
- ๐น๐ญ
Siriraj Hospital Mahidol University CRS, Bangkok, Ratchathewi, Thailand
๐น๐ญChiang Mai University Pediatrics-Obstetrics CRS, Chiang Mai, Thailand
๐น๐ญChonburi Hosp. CRS, Chonburri, Thailand
Case-Control Viramune (Nevirapine) Toxicogenomics Study
- First Posted Date
- 2006-04-05
- Last Posted Date
- 2013-08-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 889
- Registration Number
- NCT00310843
- Locations
- ๐บ๐ธ
1100.1452.01003 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States
๐บ๐ธ1100.1452.99999 Boehringer Ingelheim Investigational Site, Baltimore, Connecticut, United States
๐ฆ๐ท1100.1452.54002 Funcei, Capital Federal, Argentina
Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV
- Conditions
- Interventions
- First Posted Date
- 2006-03-28
- Last Posted Date
- 2019-12-04
- Lead Sponsor
- Germans Trias i Pujol Hospital
- Target Recruit Count
- 675
- Registration Number
- NCT00307502
- Locations
- ๐ช๐ธ
Hospital de Figueres, Figueras, Barcelona, Spain
๐ช๐ธHospital Universitari Sant Joan de Reus, Reus, Tarragona, Spain
๐ช๐ธGermans Trias i Pujol Hospital, Badalona, Barcelona, Spain
Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV
- Conditions
- Interventions
- First Posted Date
- 2006-03-27
- Last Posted Date
- 2017-04-13
- Target Recruit Count
- 452
- Registration Number
- NCT00307151
- Locations
- ๐ฟ๐ฒ
George Clinic CRS, Lusaka, Zambia
๐ฟ๐ผUZ-College of Health Sciences, Harare, Zimbabwe
๐ฎ๐ณBJ Medical College CRS, Pune, Maharashtra, India
Pharmacokinetics Study on Nevirapine Resistance in Tanzania
- Conditions
- Interventions
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 144
- Registration Number
- NCT00294892
- Locations
- ๐น๐ฟ
Kilimanjaro Christian Medical College, Moshi, Tanzania
Quality of Life and Changes in Metabolism of Lipids and Glucose After Switching to a Nevirapine-based Regimen in HIV+ Patients
- Conditions
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 158
- Registration Number
- NCT00274001
- Locations
- ๐ฎ๐น
Ospedale degli Infermi di Biella, Biella, Italy
๐ฎ๐นOspedale Civile, Piacenza, Italy
๐ฎ๐นSpedali Civili di Brescia, Brescia, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.